EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Prevention of alcohol relapse in post-liver transplant patients with alcohol use disorder

Malak Elsawy, Ali Emre Bardak, Eda Yildiz, N. Begum Ozturk, M. Deniz Toruner, Merve Gurakar, Shazil Ahmed Gangat, Can Cindoruk, Ahmet Gurakar

Hepatology Forum · 2026 · 7 (4) · 407-415

DOI: 10.14744/hf.2026.37032 ↗
AbstractBibliografische Angaben

Abstract

Alcohol-associated liver disease has become the most common reason for liver transplantation (LT) in many regions, including the US. This shift reflects the declining hepatitis C-related LTs and rising prevalence of harmful alcohol use, which increased substantially, especially during COVID-19 pandemic. Post-LT alcohol relapse leads to poor clinical outcomes, including medication non-adherence, graft dysfunction (steatosis and alcohol-related hepatitis), recurrent cirrhosis, and decreased overall survival. For patients with severe alcohol-associated hepatitis, early or expedited LT can offer a survival advantage in carefully selected candidates compared with traditional approaches requiring six months of pre-LT abstinence, without a substantial increase in hazardous relapse. Pre-LT risk assessment is essential for the candidate selection and combines psychosocial factors with validated tools such as Stanford Integrated Psychosocial Assessment for Transplantation, Hopkins psychosocial scale, sustained alcohol use post-LT, harmful alcohol use post-LT, and high-risk alcoholism relapse. Post-LT monitoring utilizing direct biomarkers (e.g., phosphatidylethanol, ethyl glucuronide) with indirect markers of alcohol-use to widen the detection window and capture both low-level and heavy use should be considered. Optimal management of alcohol-use disorder (AUD) relies on combining pharmacologic and psychosocial interventions. Among pharmacologic options, naltrexone and acamprosate are considered first-line options, whereas disulfiram is less commonly used after LT given concerns about its drug interactions. Psychosocial aspects of the management are as important as the pharmacologic aspects to maintain abstinence and reduce relapse risk. Potential barriers to participation, such as hepatic decompensation, hepatic encephalopathy, or logistical challenges, should also be recognized and addressed. This narrative review summarizes current management strategies for AUD with emphasis on the post-LT setting.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →